We are live on ! Find out more
BJCM

Blue Jay Capital Management Portfolio holdings

AUM $147M
1-Year Est. Return 64.18%
This Fund
S&P 500
This Quarter Est. Return
+25.88%
1 Year Est. Return
+64.18%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$183M
AUM Growth
+$30.9M
Cap. Flow
+$10.5M
Cap. Flow %
5.75%
Top 10 Hldgs %
65.14%
Holding
25
New
11
Increased
1
Reduced
5
Closed
8

Top Buys

Rank Stock Value
1
HOLX
Hologic
HOLX
+$11.5M
2
TSRO
TESARO, Inc.
TSRO
+$11.2M
3
WMGI
Wright Medical Group Inc
WMGI
+$11.2M
4
SNN icon
Smith & Nephew
SNN
+$10.9M
5
INCY icon
Incyte
INCY
+$10.8M

Top Sells

Rank Stock Value
1
SGEN
Seagen Inc. Common Stock
SGEN
+$13.3M
2
MJN
Mead Johnson Nutrition Company
MJN
+$12.3M
3
ABMD
Abiomed Inc
ABMD
+$11.5M
4
BSX icon
Boston Scientific
BSX
+$11M
5
VRTX icon
Vertex Pharmaceuticals
VRTX
+$10.8M

Sector Composition

Rank Sector Weight
1 Healthcare 95.51%
2 Miscellaneous 4.49%
3 Consumer Staples 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BIIB icon
1
Biogen
BIIB
$32.6B
$12.8M 7.01%
40,996
+996
+2% +$295K
BMRN icon
2
BioMarin Pharmaceuticals
BMRN
$12.9B
$12.7M 6.95%
137,595
-14,658
-10% -$1.38M
INCY icon
3
Incyte
INCY
$25.7B
$12.1M 6.6%
+128,169
New +$10.8M
CLVS
4
DELISTED
Clovis Oncology, Inc.
CLVS
$12.1M 6.59%
+335,000
New +$7.19M
TSRO
5
DELISTED
TESARO, Inc.
TSRO
$12M 6.57%
+120,000
New +$11.2M
WMGI
6
DELISTED
Wright Medical Group Inc
WMGI
$11.9M 6.51%
+486,180
New +$11.2M
HOLX
7
DELISTED
Hologic
HOLX
$11.9M 6.48%
+305,474
New +$11.5M
IRWD icon
8
Ironwood Pharmaceuticals
IRWD
$704M
$11.5M 6.29%
865,650
-114,708
-12% -$1.34M
NBIX icon
9
Neurocrine Biosciences
NBIX
$15.8B
$11.5M 6.26%
226,501
-79,129
-26% -$3.94M
ILMN icon
10
Illumina
ILMN
$33B
$10.8M 5.88%
+60,930
New +$9.75M
SNN icon
11
Smith & Nephew
SNN
$12.1B
$10.7M 5.82%
+325,000
New +$10.9M
MASI
12
DELISTED
Masimo
MASI
$9.88M 5.4%
166,131
-52,829
-24% -$2.98M
DERM
13
DELISTED
Dermira, Inc.
DERM
$9.3M 5.08%
+275,000
New +$8.86M
PRGO icon
14
Perrigo
PRGO
$2.07B
$9.23M 5.04%
+100,000
New +$9.21M
NUVA
15
DELISTED
NuVasive, Inc.
NUVA
$8.64M 4.72%
129,680
-29,980
-19% -$1.91M
QGENF
16
DELISTED
QIAGEN NV
QGENF
$8.23M 4.49%
+300,000
New +$8.23M
MDRX
17
DELISTED
Veradigm Inc. Common Stock
MDRX
$7.9M 4.31%
+600,000
New +$8.02M
BSX icon
18
Boston Scientific
BSX
$69.3B
– –
-469,900
Closed -$11M
MOH icon
19
Molina Healthcare
MOH
$10.5B
– –
-205,270
Closed -$10.2M
VRTX icon
20
Vertex Pharmaceuticals
VRTX
$138B
– –
-125,450
Closed -$10.8M
SGEN
21
DELISTED
Seagen Inc. Common Stock
SGEN
– –
-328,430
Closed -$13.3M
ABMD
22
DELISTED
Abiomed Inc
ABMD
– –
-104,920
Closed -$11.5M
AGN
23
DELISTED
Allergan plc
AGN
– –
-36,940
Closed -$8.54M
MJN
24
DELISTED
Mead Johnson Nutrition Company
MJN
– –
-135,045
Closed -$12.3M
SHPG
25
DELISTED
Shire pic
SHPG
– –
-41,060
Closed -$7.56M

Similar funds

BCM
Breithorn Capital Management New York $141M AUM 41.82% 1-Year Est. Return
RJA
Robshaw & Julian Associates Williamsville, New York $140M AUM 13.69% 1-Year Est. Return
RP
Ridgegate Proprietary Sydney, Australia $154M AUM 25.47% 1-Year Est. Return
ACPVT
ABS Capital Partners V Trust Baltimore, Maryland $123M AUM
SFA
Staton Financial Advisors Charlotte, North Carolina $118M AUM 11.07% 1-Year Est. Return
KL
Kinsight LLC Birmingham, Alabama $176M AUM 17.21% 1-Year Est. Return
AIM
Acrospire Investment Management Chicago, Illinois $107M AUM 37.25% 1-Year Est. Return
KFS
Kissinger Financial Services Hunt Valley, Maryland $100M AUM 6.22% 1-Year Est. Return

Blue Jay Capital Management's Q3 2016 Portfolio in Review

As of Q3 2016, Blue Jay Capital Management held 25 positions worth $183M, up 20% from $152M the previous quarter. Its ten largest holdings account for 65% of the portfolio.

Blue Jay Capital Management deployed $10.5M of net new capital in Q3 2016, opening 11 new positions and adding to 1 existing holding. Its largest new stake was Hologic: 305,474 shares worth $11.9M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 92% a quarter earlier, followed by Miscellaneous and Consumer Staples.

On the sell side, the largest reduction was Neurocrine Biosciences, an estimated $3.94M trimmed.

  • Blue Jay Capital Management's largest Q3 2016 buy was Hologic: 305,474 shares worth $11.9M.
  • Blue Jay Capital Management added most to Biogen in Q3 2016, an estimated $295K increase.
  • Blue Jay Capital Management's biggest Q3 2016 reduction was Neurocrine Biosciences, cutting an estimated $3.94M.
  • Blue Jay Capital Management fully exited Seagen Inc. Common Stock in Q3 2016, selling an estimated $13.3M.
  • Blue Jay Capital Management's ten largest holdings make up 65% of its $183M portfolio in Q3 2016.
  • Blue Jay Capital Management opened 11 new positions and closed 8 in Q3 2016.
  • Blue Jay Capital Management's portfolio value rose 20% quarter-over-quarter to $183M.

Based on Blue Jay Capital Management's 13F filing for Q3 2016, filed 10 Nov 2016.